Where capital is flowing and why the tape moves, across funding rounds, M&A, IPOs and market analysis.
Page 3 of 15
Oct 2, 2026Third-quarter biopharma M&A cooled materially from the prior quarter, with spending falling to just under $30 billion across 22 transactions, according to S&P Capital IQ figures cited by BioSpace. Vertex stood out in that quieter market with a Crinetics acquisition originally tallied at $10 billion by the companies, or $8.8 billion including debt and other factors by S&P Capital IQ.
Sep 29, 2026The deal has three parts: AstraZeneca will buy convertible preferred stock equivalent to about 12% of Summit at a premium to Summit’s Monday closing price, jointly fund clinical trials pairing ivonescimab with sonesitatug vedotin, and set up a nonbinding framework for additional combinations. The move signals AstraZeneca sees value in using a PD-1xVEGF bispecific as a combination backbone for its ADC portfolio ahead of a global Phase 3 readout.
Sep 29, 2026The company said it has now raised $430 million in total, pairing fresh capital with an FDA 510(k) approval won in March 2025 for a temporary Layer 7 cortical interface developed with Medtronic. The investment signal is that backers are still willing to fund BCI companies that can show regulatory progress, clinical access and a path to commercialization infrastructure.
Sep 25, 2026ADARx sold 26.25 million shares at $17, above its earlier expectations, and could raise more if underwriters exercise an option for another 3.9 million shares. A concurrent $100 million private placement from AbbVie adds strategic validation as the company funds multiple siRNA programs, while City Therapeutics signals that investor appetite for RNA remains open beyond a single issuer.
Sep 23, 2026Enveda said the new capital will support advancement of two programs that have already generated early human data and a third asset in phase 1, while also helping move earlier candidates into the clinic. For a company built around nature-derived chemistry and AI, the round shifts the focus from platform promise to whether it can repeatedly convert early clinical signals into a development-stage business.
Sep 23, 2026The Swiss drugmaker said the agreement complements its radioligand portfolio, even though details of the licensed program were not disclosed. The timing is notable: Novartis is reinforcing a core oncology franchise just after abandoning one midstage asset and as a stronger rival platform begins to form around Telix and ITM.
Sep 21, 2026TRex would use IPO proceeds to move a Treg-focused autoimmune pipeline forward, while Retension is centered on taking RTN-001 through a phase 2b study and into phase 3 in uncontrolled hypertension. The paired filings suggest the current IPO window is open to very different biotech profiles, as long as the use of capital is tightly linked to near-term development steps.
Sep 20, 2026The Boston-based company serves employers, payers and providers with virtual care for digestive issues including abdominal pain, bloating, constipation and weight gain. The new round, led by Neon, brings Ayble Health’s total funding to more than $27 million and signals investor interest in specialty virtual care models that are trying to connect overlapping chronic conditions rather than treat them separately.
Sep 18, 2026Electra sold 23.3 million shares at $15 each, with underwriters holding a 30-day option to buy up to 3.5 million more shares. The company plans to direct most of the proceeds toward ipsoprubart in secondary hemophagocytic lymphohistiocytosis and related malignancy studies, while also advancing ELA822.
Sep 11, 2026The raise adds to a month that has already featured multiple sizable life sciences financings. For investors and biotech executives, the signal is that specialist capital is still being assembled for public-company opportunities even as the sector remains selective about where that money goes.
Sep 10, 2026The New York-based firm said LumaBio Fund I is designed to support companies from discovery through commercialization. Its existing portfolio includes Character Biosciences, Coultreon Biopharma and Altos Labs, and one co-founded company, Vaccine Company, was acquired by Eli Lilly earlier this year for up to $1.55 billion.
Sep 10, 2026The financing backs both late-development execution and infrastructure, with Encoded pairing a registration-directed program in Dravet syndrome with a commercial manufacturing build-out. That combination signals that investors are still willing to fund genetic medicines when companies can point to clinical traction and a clearer path toward control of supply.
Machine learning, predictive models and computational biology: how AI is changing discovery workflows and probability of success.
Drug development, clinical trials and industry dynamics. What changes timelines, risk and competitive positioning.
Gene therapy, CRISPR, synthetic biology and emerging platforms. Separating what is real from what is hype, and what actually translates.
Digital health, diagnostics and medical devices, and the signals that matter for adoption, reimbursement and outcomes.
FDA actions, approvals, policy shifts and compliance: how the rules change timelines and probability.